Community Trust & Investment Co. Increases Stake in IQVIA Holdings Inc. $IQV

Community Trust & Investment Co. lifted its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 5.0% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 92,668 shares of the medical research company’s stock after buying an additional 4,388 shares during the quarter. Community Trust & Investment Co.’s holdings in IQVIA were worth $17,905,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the company. Elevation Wealth Partners LLC lifted its stake in IQVIA by 218.8% in the second quarter. Elevation Wealth Partners LLC now owns 153 shares of the medical research company’s stock worth $30,000 after acquiring an additional 105 shares during the last quarter. Czech National Bank increased its position in shares of IQVIA by 2.8% in the 2nd quarter. Czech National Bank now owns 47,506 shares of the medical research company’s stock valued at $9,179,000 after purchasing an additional 1,316 shares during the last quarter. PensionDanmark Pensionsforsikringsaktieselskab raised its holdings in shares of IQVIA by 9.8% in the 2nd quarter. PensionDanmark Pensionsforsikringsaktieselskab now owns 30,122 shares of the medical research company’s stock valued at $5,820,000 after purchasing an additional 2,700 shares in the last quarter. Assenagon Asset Management S.A. lifted its position in shares of IQVIA by 47.3% during the 2nd quarter. Assenagon Asset Management S.A. now owns 340,476 shares of the medical research company’s stock worth $65,787,000 after purchasing an additional 109,284 shares during the last quarter. Finally, GAMMA Investing LLC lifted its position in shares of IQVIA by 17.1% during the 2nd quarter. GAMMA Investing LLC now owns 3,413 shares of the medical research company’s stock worth $659,000 after purchasing an additional 498 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Stock Up 2.4%

IQV stock opened at $237.97 on Friday. The stock has a market capitalization of $39.17 billion, a PE ratio of 29.53, a price-to-earnings-growth ratio of 1.97 and a beta of 1.18. The company has a fifty day moving average of $200.92 and a 200-day moving average of $186.95. The company has a debt-to-equity ratio of 2.18, a quick ratio of 0.71 and a current ratio of 0.71. IQVIA Holdings Inc. has a one year low of $154.50 and a one year high of $251.36.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, beating analysts’ consensus estimates of $3.03 by $0.12. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The company had revenue of $4.37 billion for the quarter, compared to analyst estimates of $4.30 billion. During the same quarter in the previous year, the company earned $2.81 EPS. The firm’s revenue for the quarter was up 8.7% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. As a group, analysts expect that IQVIA Holdings Inc. will post 11.57 EPS for the current year.

IQVIA announced that its Board of Directors has approved a share buyback plan on Thursday, May 7th that allows the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization allows the medical research company to repurchase up to 6.8% of its shares through open market purchases. Shares repurchase plans are often an indication that the company’s management believes its shares are undervalued.

Insider Activity at IQVIA

In other news, insider Eric Sherbet sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 29th. The stock was sold at an average price of $249.16, for a total transaction of $1,245,800.00. Following the sale, the insider owned 20,999 shares of the company’s stock, valued at $5,232,110.84. The trade was a 19.23% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Keriann Cherofsky sold 558 shares of the firm’s stock in a transaction that occurred on Wednesday, July 29th. The shares were sold at an average price of $245.21, for a total value of $136,827.18. Following the completion of the transaction, the insider directly owned 2,989 shares of the company’s stock, valued at $732,932.69. The trade was a 15.73% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 12,913 shares of company stock valued at $3,098,793 in the last 90 days. Insiders own 1.70% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the company. TD Cowen increased their target price on IQVIA from $233.00 to $288.00 and gave the company a “buy” rating in a report on Wednesday, July 29th. Wall Street Zen raised IQVIA from a “hold” rating to a “buy” rating in a report on Saturday, August 1st. Deutsche Bank Aktiengesellschaft set a $240.00 price objective on shares of IQVIA in a report on Thursday, July 9th. Robert W. Baird increased their target price on shares of IQVIA from $252.00 to $287.00 and gave the company an “outperform” rating in a research report on Wednesday, July 29th. Finally, Barclays reissued an “overweight” rating on shares of IQVIA in a research report on Tuesday, July 28th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $241.88.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real?world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real?world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.